Sun Pharma Receives Mixed CDSCO Decisions on Dermatology Drug Trials
核心洞察
CDSCO (搜索) panel approved Sun Pharma's Phase III clinical trial for ruxolitinib cream 1.5% to treat non-segmental vitiligo in patients 12 years and older.
The regulatory committee required Sun Pharma to revise its Phase III trial protocol for roflumilast cream 0.3% for plaque psoriasis treatment.
Both topical treatments target different dermatological conditions through distinct mechanisms of action, with ruxolitinib being a JAK (搜索) inhibitor and roflumilast a PDE4 (搜索) inhibitor.
India's Central Drugs Standard Control Organisation (CDSCO (搜索)) has delivered contrasting decisions on two dermatology drug applications from Sun Pharmaceutical Industries, approving one Phase III trial while requiring significant protocol revisions for another.
Ruxolitinib Cream Gains Trial Approval
The CDSCO (搜索) Subject Expert Committee (SEC) approved Sun Pharma's Phase III clinical trial for ruxolitinib cream 1.5% w/w, intended for topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older. This approval came after the company successfully justified its selection of decapeptide as the comparator arm, addressing earlier regulatory concerns raised in April 2025.
Ruxolitinib is a Janus kinase (JAK (搜索)) inhibitor that received approval in the United States in July 2022 for the same indication. Non-segmental vitiligo, also known as generalized vitiligo, represents the most common form of vitiligo, characterized by symmetrical white patches appearing on both sides of the body. The condition results from autoimmune destruction of melanocytes, the cells responsible for producing skin pigment.
The regulatory panel had previously noted that the mechanisms of action between the comparator arm decapeptide and the proposed ruxolitinib cream differ significantly. Following Sun Pharma's presentation of justification for the comparator selection and standardization of sunlight/commercial UVB light protocols, the committee granted approval for the Phase III study under protocol No. ICR/24/008 Version 1.0.
Roflumilast Protocol Requires Revision
In contrast, the CDSCO (搜索) panel mandated substantial revisions to Sun Pharma's Phase III trial protocol for roflumilast cream 0.3% w/w, proposed as an alternative treatment for plaque psoriasis. The company had sought permission to manufacture and market the topical formulation along with a bioequivalence study waiver.
Roflumilast functions as a selective phosphodiesterase-4 inhibitor, currently indicated to decrease exacerbation risk in patients with severe chronic obstructive pulmonary disease and to treat skin conditions including plaque psoriasis and atopic dermatitis. The drug and its active metabolite roflumilast N-oxide inhibit PDE4 (搜索), a major cyclic adenosine monophosphate metabolizing enzyme, leading to intracellular cyclic AMP accumulation.
Specific Protocol Modifications Required
The expert committee outlined six specific changes required for the roflumilast Phase III protocol:
The study power must increase to 95%, necessitating an expanded participant pool. Treatment duration should extend to 12 weeks, with at least 50% of patients requiring 6-8 months of post-treatment follow-up to monitor lesion clearance or reduction.
Additionally, at least 10% of patients or 30 individuals must undergo biopsy testing with pathological evaluation at follow-up completion, with baseline biopsies preferred. The committee also mandated photographic documentation of lesion measurements against rulers or scales as part of the clinical study report to verify changes in lesion color and size.
The panel further required specification of toxic dose levels for systemic absorption through skin application, reflecting safety considerations for topical administration.
Regulatory Context
Sun Pharma informed the committee that roflumilast cream 0.3% w/w has received approval in both Canada and the United States for the proposed plaque psoriasis indication. However, the CDSCO (搜索)'s requirements demonstrate the regulatory body's emphasis on comprehensive safety and efficacy documentation tailored to the Indian patient population.
These decisions underscore CDSCO (搜索)'s rigorous evaluation process for dermatology therapeutics, balancing innovation access with patient safety through enhanced study parameters and methodological requirements.